Patents by Inventor Frances H. Arnold

Frances H. Arnold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160251642
    Abstract: The disclosure provides variant Ce16a enzymes having increased thermostability, methods of making and using such polypeptides.
    Type: Application
    Filed: April 25, 2016
    Publication date: September 1, 2016
    Inventors: Frances H. Arnold, Indira Wu
  • Patent number: 9399762
    Abstract: The disclosure generally relates to the fields of synthetic organic chemistry. In particular, the present disclosure relates to methods and systems for the imidation of sulfides.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: July 26, 2016
    Assignee: California Institute of Technology
    Inventors: Christopher C. Farwell, John A. McIntosh, Frances H. Arnold
  • Patent number: 9334517
    Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: May 10, 2016
    Assignee: California Institute of Technology
    Inventors: Toni M. Lee, Stephen L. Mayo, Frances H. Arnold, Devin Trudeau
  • Patent number: 9334544
    Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a. A variant Cel5a endoglucanase is combined with variant Cel6a and variant Cel7a cellobiohydrolases resulting in more effective hydrolysis of cellulose.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: May 10, 2016
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Devin L. Trudeau, Frances H. Arnold, Toni M. Lee, Stephen L. Mayo
  • Patent number: 9322001
    Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.
    Type: Grant
    Filed: May 10, 2014
    Date of Patent: April 26, 2016
    Assignee: California Institute of Technology
    Inventors: Edgardo Farinas, Frances H. Arnold, Ulrich Schwaneberg, Anton Glieder
  • Patent number: 9322007
    Abstract: The disclosure provides variant Cel6a enzymes having increased thermostability, methods of making and using such polypeptides.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: April 26, 2016
    Assignee: The California Institute of Technology
    Inventors: Frances H. Arnold, Indira Wu
  • Patent number: 9284587
    Abstract: The present disclosure relates to CBH I chimera fusion polypeptides, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 15, 2016
    Assignee: California Institute of Technology
    Inventors: Frances H. Arnold, Pete Heinzelman
  • Patent number: 9249401
    Abstract: The present disclosure relates to CBH II chimera fusion polypeptides, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: February 2, 2016
    Assignee: California Institute of Technology
    Inventors: Frances H. Arnold, Pete Heinzelman
  • Publication number: 20160002682
    Abstract: The present invention provides methods for catalyzing the conversion of an olefin to any compound containing one or more cyclopropane functional groups using heme enzymes. In certain aspects, the present invention provides a method for producing a cyclopropanation product comprising providing an olefinic substrate, a diazo reagent, and a heme enzyme; and admixing the components in a reaction for a time sufficient to produce a cyclopropanation product. In other aspects, the present invention provides heme enzymes including variants and fragments thereof that are capable of carrying out in vivo and in vitro olefin cyclopropanation reactions. Expression vectors and host cells expressing the heme enzymes are also provided by the present invention.
    Type: Application
    Filed: February 18, 2015
    Publication date: January 7, 2016
    Inventors: PEDRO S. COELHO, Eric M. Brustad, Frances H. Arnold, Zhan Wang, Jared C. Lewis
  • Patent number: 9145549
    Abstract: Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: September 29, 2015
    Assignee: The California Institute of Technology
    Inventors: Frances H. Arnold, Matthew W. Peters, Peter Meinhold
  • Publication number: 20150267232
    Abstract: This invention relates to the use of heme-containing enzymes to catalyze carbene and nitrene insertion and transfer reactions with greater selectivity, mild reaction conditions, and convenient production.
    Type: Application
    Filed: April 1, 2015
    Publication date: September 24, 2015
    Applicant: California Institute of Technology
    Inventors: PEDRO COELHO, Frances H. Arnold, Jared C. Lewis, Zhan Wang
  • Publication number: 20150259657
    Abstract: The disclosure provides variant Cel6a enzymes having increased thermostability, methods of making and using such polypeptides.
    Type: Application
    Filed: July 20, 2012
    Publication date: September 17, 2015
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Frances H. Arnold, Indira Wu
  • Publication number: 20150232814
    Abstract: The disclosure generally relates to the fields of synthetic organic chemistry. In particular, the present disclosure relates to methods and systems for the imidation of sulfides.
    Type: Application
    Filed: February 18, 2015
    Publication date: August 20, 2015
    Inventors: Christopher C. Farwell, John A. McIntosh, Frances H. Arnold
  • Publication number: 20150159187
    Abstract: The present disclosure relates to CBH I chimera fusion polypeptides, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.
    Type: Application
    Filed: February 18, 2015
    Publication date: June 11, 2015
    Inventors: Frances H. Arnold, Pete Heinzelman
  • Patent number: 8993262
    Abstract: The present invention provides methods for catalyzing the conversion of an olefin to any compound containing one or more cyclopropane functional groups using heme enzymes. In certain aspects, the present invention provides a method for producing a cyclopropanation product comprising providing an olefinic substrate, a diazo reagent, and a heme enzyme; and admixing the components in a reaction for a time sufficient to produce a cyclopropanation product. In other aspects, the present invention provides heme enzymes including variants and fragments thereof that are capable of carrying out in vivo and in vitro olefin cyclopropanation reactions. Expression vectors and host cells expressing the heme enzymes are also provided by the present invention.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: March 31, 2015
    Assignee: California Institute of Technology
    Inventors: Pedro S. Coelho, Eric M. Brustad, Frances H. Arnold, Zhan Wang, Jared C. Lewis
  • Patent number: 8962295
    Abstract: The present disclosure relates to CBH I chimera fusion polypeptides, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: February 24, 2015
    Assignee: California Institute of Technology
    Inventors: Frances H. Arnold, Pete Heinzelman
  • Publication number: 20150050701
    Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a. A variant Cel5a endoglucanase is combined with variant Cel6a and variant Cel7a cellobiohydrolases resulting in more effective hydrolysis of cellulose.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 19, 2015
    Inventors: Devin L. Trudeau, Frances H. Arnold, Toni M. Lee, Stephen L. Mayo
  • Publication number: 20150010976
    Abstract: Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.
    Type: Application
    Filed: June 2, 2014
    Publication date: January 8, 2015
    Inventors: Frances H. Arnold, Matthew W. Peters, Peter Meinhold
  • Publication number: 20140322792
    Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.
    Type: Application
    Filed: May 10, 2014
    Publication date: October 30, 2014
    Applicant: The California Institute of Technology
    Inventors: Edgardo Farinas, Frances H. Arnold, Ulrich Schwaneberg, Anton Glieder
  • Publication number: 20140308713
    Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 16, 2014
    Inventors: Toni M. Lee, Stephen L. Mayo, Frances H. Arnold, Devin Trudeau